Pharmacologic class (EPC) · 18 drug pages

GLP-1 receptor agonist: adverse event reports filed with FDA

404,853 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

404,853
reports across the class: 2% of all reports; 115,535
reports, 12 months to June 2026: 65,552 in the 12 months before; 28%
marked serious by the reporter: 57.4% across all reports; 18
drugs with a page: brand and generic names counted separately

GLP-1 receptor agonist is a pharmacologic class (an FDA Established Pharmacologic Class) with 18 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 404,853 adverse event reports received by FDA, 2% of the database, from June 2004 to June 2026.

115,535 reports arrived in the 12 months to June 2026, up 76% from 65,552 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 28% of the class's reports are marked serious, 1.5% record death among the outcomes and 11.3% record hospitalisation, as reported.

Across the class the reactions recorded most often are nausea (14.4%), incorrect dose administered (9.3%) and blood glucose increased (8.2%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
MounjaroTirzepatide	brand	85,842	26,334	23.6%	Incorrect dose administered
TrulicityDulaglutide	brand	75,864	4,282	20.7%	Injection site pain
ZepboundTirzepatide	brand	63,628	40,900	6.2%	Incorrect dose administered
OzempicSemaglutide	brand	52,881	21,704	48.8%	Nausea
ByettaExenatide	brand	47,928	12	24.7%	Blood glucose increased
VictozaLiraglutide	brand	28,899	998	41.8%	Nausea
WegovySemaglutide	brand	19,509	11,958	45.4%	Nausea
SaxendaLiraglutide	brand	6,598	471	47.3%	Nausea
RybelsusOral semaglutide	brand	6,055	1,532	56%	Nausea
Semaglutide	generic	4,499	1,830	71%	Nausea
Soliqua 100/33Insulin glargine and lixisenatide	brand	3,153	413	14.6%	Blood glucose increased
Tirzepatide	generic	2,522	1,257	58.4%	Product tampering
Zepbound KwikpenTirzepatide	brand	2,396	2,396	5.1%	Incorrect dose administered
Liraglutide	generic	1,446	475	66.2%	Dyspnoea
Insulin degludec and liraglutide	generic	1,197	141	72.9%	Blood glucose increased
Dulaglutide	generic	994	104	68.3%	Nausea
FoundayoOrforglipron	brand	723	723	2.8%	Nausea
Exenatide	generic	719	5	79.4%	Nausea

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Nauseafeeling sick14.4%58,348
Incorrect dose administeredthe wrong dose was given9.3%37,669
Blood glucose increasedraised blood sugar reading8.2%33,376
Vomitingbeing sick7.4%29,795
Diarrhoealoose or frequent stools6.9%27,802
Injection site painpain where the injection was given6.6%26,773
Weight decreasedweight loss5.8%23,390
Off label useused for a purpose or in a way not on the label5.1%20,550
Decreased appetitereduced appetite4.7%18,959
Constipationconstipation4.2%16,822
Drug ineffectivethe medicine did not work as expected3.6%14,676
Extra dose administered3.2%13,101
Abdominal pain upperupper stomach pain3%11,968
Fatiguetiredness2.9%11,769
Headachehead pain2.7%11,110
Injection site haemorrhagebleeding where the injection was given2.7%10,884
Dizzinesslight-headedness or unsteadiness2.7%10,815
Blood glucose decreasedlow blood sugar reading2.6%10,479
Weight increasedweight gain2.5%10,114
Abdominal painstomach or belly pain2.3%9,415
Pancreatitisinflammation of the pancreas2.1%8,694
Inappropriate schedule of product administrationthe product was taken at the wrong times2%8,176
Impaired gastric emptying2%8,150
Dyspepsiaindigestion2%8,131
Malaisegeneral feeling of being unwell2%8,093

Solid bar: share of all class reports. Hollow bar: the median share across the 18 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death1.5%5,928

Life-threatening1.2%4,950

Hospitalisation (initial or prolonged)11.3%45,920

Disability1%4,152

Congenital anomaly0%163

Other serious19.4%78,343

Not serious72%291,479

Patient age

Under 20%93

2 to 110%57

12 to 170.1%332

18 to 4410.4%42,241

45 to 6429.5%119,415

65 to 7414.3%57,749

75 and over5.7%23,200

Age not given40%161,766

Who reported

Physician8%32,291

Pharmacist2.4%9,788

Other health professional5.8%23,480

Lawyer1%3,908

Consumer or non-health professional82%332,023

Not given0.8%3,363

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about GLP-1 receptor agonist reports

Which drugs are in the GLP-1 receptor agonist class on this site?

Mounjaro, Trulicity, Zepbound, Ozempic, Byetta and Victoza and 12 more. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

404,853 reports through June 2026, 115,535 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

nausea (14.4%), incorrect dose administered (9.3%), blood glucose increased (8.2%), vomiting (7.4%) and diarrhoea (6.9%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.